BSMHWebadmin, Author at Clinical Trials Portal

Alliance 212102

Alliance Protocol A212102, “Blinded Reference Set for Multicancer Early Detection Blood Tests”

https://www.clinicaltrials.gov/ct2/show/NCT05334069?term=NCT05334069&draw=2&rank=1

S2001

“Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations”

A021703

RANDOMIZED DOUBLE-BLIND PHASE III TRIAL OF VITAMIN D3 SUPPLEMENTATION IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (SOLARIS)

URCC21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT):A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)(NCT04181060)

NRG-GI008

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

SWOG 2001

A Phase II Trial of Sacituzumab Govitecan (TRODELVY™) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

S2007

A Phase II Trial of Sacituzumab Govitecan (TRODELVY™) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.”

A191901

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions,”

Author: BSMHWebadmin